上海国资，收购一家上市公司

Core Viewpoint - The article discusses the acquisition of Kanghua Biological by Shanghai Wankexin Biotechnology, led by Wang Zhentao, the controlling shareholder, marking a significant shift in the company's ownership structure and reflecting broader trends in the biopharmaceutical industry in Shanghai [3][11]. Group 1: Acquisition Details - Kanghua Biological's controlling shareholder Wang Zhentao and his associates plan to transfer shares worth a total of 1.851 billion yuan to Shanghai Wankexin, making it the new controlling shareholder [3][11]. - The share transfer involves 2,846,666 shares, representing 21.91% of the total share capital after excluding repurchased shares [11]. - Wankexin was established on July 8, 2025, and is backed by several state-owned enterprises, including Shanghai Pharmaceutical Group and Shanghai Shenshi Biomedical Management Consulting [11][13]. Group 2: Background of Wang Zhentao - Wang Zhentao, known as the "Wenzhou Shoe King," founded Aokang International in 1988 and later ventured into the vaccine industry in 2002 by establishing Kanghua Biological [6][7]. - Kanghua Biological became notable for its freeze-dried human rabies vaccine, the first of its kind to be listed in China [8]. - Despite initial success, Aokang International faced declining profits, leading to a strategic decision to sell Kanghua Biological as a means of survival [9][8]. Group 3: Industry Context - The biopharmaceutical sector in Shanghai is undergoing significant consolidation, with the city promoting mergers and acquisitions as a strategy for industry growth [15]. - Shanghai has established a 100 billion yuan biopharmaceutical industry merger fund to support this initiative, aiming for a total merger transaction scale of 3000 billion yuan by 2027 [15]. - The article highlights the competitive landscape in the biopharmaceutical industry, emphasizing the importance of high-quality mergers and acquisitions for business expansion and industry strength [15].